Previous Article | Next Article ![]()
Infect. Immun., May 1997, 1584-1592, Vol 65, No. 5
YC Chang, R Cherniak, TR Kozel, DL Granger, LC Morris, LC Weinhold and KJ Kwon- Chung
The extracellular polysaccharide capsule of Cryptococcus neoformans is a
well-recognized virulence factor. Strain 602 is an acapsular clinical
isolate of unknown serotype which has been widely used in studies of
virulence and host-parasite interactions. In previous studies, strain 602
was compared with genetically unrelated strains of various serotypes
because the wild-type equivalent of strain 602 was not available. We
created an encapsulated strain, TYCC38-602, by transforming strain 602 with
the CAP64 gene which was isolated from a serotype D strain. Serological
tests and chemical analysis of the major polysaccharide capsule of
TYCC38-602 indicated that strain 602 was originally derived from a serotype
A strain. Restoration of the ability to produce a capsule enabled strain
602 to cause fatal infection in mice, whereas the acapsular strain 602
remained avirulent. Capsule- restored yeast cells of strain 602 activated
the human complement system and bound C3 fragments in a manner that is
characteristic of encapsulated cryptococci. In addition, the capsule in
TYCC38-602 masked the ability of the organism to induce tumor necrosis
factor alpha and subsequent nitric oxide synthase production in primed
macrophage-like cells. These results indicate that the lack of capsule in
strain 602 is the reason for its inability to cause fatal infection.
Moreover, the acapsular phenotype accounts for differences in various
biological activities of strain 602 compared to encapsulated strains. The
results also indicate that the gene product of CAP64 does not contribute to
serotype specificity of capsules in C. neoformans.
Copyright © 1997, American Society for Microbiology
Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene
Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|